Tegaderm transparent dressing (3M) for the treatment of chronic exposure keratopathy.
We report an effective alternative treatment of profound chronic exposure keratopathy in a proptotic eye due to intraorbital extension of basal cell carcinoma. The corneal surface gradually reepithelialized in a 6-week period after the first application of Tegaderm transparent dressing (3M, St. Paul, MN, U.S.A.) with instillation of antibiotic ointment on the ocular surface. The patient has been comfortable with an intact epithelial surface, a vascularized cornea, and nonirritated surrounding skin after changing the Tegaderm dressing daily for 15 months. There was no evidence of recurrent corneal ulceration or infiltrations. We conclude that Tegaderm represents a useful treatment of exposure keratopathy due to chronic proptosis.
Airiani
Suzanna
S
The Edward S. Harkness Eye Institute, College of Physicians and Surgeons of Columbia University, Columbia Presbyterian Medical Center, 635 West 165th St. Box 39, New York, NY 10032, U.S.A.
Braunstein
Richard E
RE
Kazim
Michael
M
Schrier
Amilia
A
Auran
James D
JD
Srinivasan
B Dobli
BD
D000368:Aged; D002280:Basal Cell Carcinoma / Q000150:complications / Q000601:surgery; D002908:Chronic Disease; D003320:Corneal Ulcer / Q000209:etiology / Q000473:pathology / Q000628:therapy*; D019573:Epithelium, Corneal / Q000473:pathology; D005094:Exophthalmos / Q000209:etiology; D006801:Humans; D008297:Male; D009779:Occlusive Dressings; D009918:Orbital Neoplasms / Q000150:complications / Q000601:surgery; D011140:Polyurethanes / Q000627:therapeutic use*; D016896:Treatment Outcome
D011140:Polyurethanes